Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation

Biomaterials

Volumn 29, Issue 29, 2008, Pages 4022-4028

  Steinhauser, Isabel M ^a   Langer, Klaus ^a   Strebhardt, Klaus M ^a   Spänkuch, Birgit ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Albumin; Antisense; Drug delivery; Heat stabilisation; Nanoparticle; Polo like kinase 1

Indexed keywords

ALDEHYDES; CHEMICAL PROPERTIES; CHEMICAL STABILITY; CHEMOTHERAPY; CROSSLINKING; DEGRADATION; DENATURATION; DRUG DELIVERY; DRUG DOSAGE; GENE EXPRESSION; INTERNET; LEAD; METAL RECOVERY; MONOCLONAL ANTIBODIES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; OLIGONUCLEOTIDES; SULFATE MINERALS; TUMORS;

ANTISENSE OLIGONUCLEOTIDE (ASO); ANTISENSE OLIGONUCLEOTIDES (AS ODN); CARRIER SYSTEMS; CHEMICAL CROSS-LINKING; ENZYMATIC DEGRADATION; GLUTARALDEHYDE (GTA); HEAT DENATURATION; HUMAN SERUM ALBUMIN (HSA); MONODISPERSE NANOPARTICLES; PHYSICO-CHEMICAL PROPERTIES; POLO-LIKE KINASE; PREPARATION CONDITIONS; PROTEIN EXPRESSIONS; QUANTITATIVE REAL TIME PCR (QRT PCR); SIGNIFICANT REDUCTION; TARGET CELLS; TARGETED DRUG DELIVERY; TRASTUZUMAB; TUMOUR CELLS; WESTERN BLOTTING;

NANOPARTICLES;

ANTISENSE OLIGONUCLEOTIDE; GLUTARALDEHYDE; MESSENGER RNA; NANOCARRIER; POLO LIKE KINASE 1; SERUM ALBUMIN; TRASTUZUMAB;

ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS LINKING; DENATURATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYMATIC DEGRADATION; ENZYME STABILITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TARGET CELL; TEMPERATURE; THERMOSTABILITY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEAT; HUMANS; MATERIALS TESTING; MOLECULAR STRUCTURE; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN DENATURATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SERUM ALBUMIN; SURFACE PROPERTIES;

EID: 48349096755     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.07.001     Document Type: Article

References (41)

1. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9 (2007) E128-E147
2. Vasir J.K., and Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 4 (2005) 363-374
3. Couvreur P., and Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 23 (2006) 1417-1450
4. Strebhardt K., and Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6 (2006) 321-330
5. Barr F.A., Sillje H.H., and Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5 (2004) 429-440
6. Spankuch-Schmitt B., Bereiter-Hahn J., Kaufmann M., and Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94 (2002) 1863-1877
7. Spankuch-Schmitt B., Wolf G., Solbach C., Loibl S., Knecht R., Stegmuller M., et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21 (2002) 3162-3171
8. Liu X., Lei M., and Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26 (2006) 2093-2108
9. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1489 (1999) 53-68
10. Jansen B., and Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol 3 (2002) 672-683
11. Arnedo A., Espuelas S., and Irache J.M. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 244 (2002) 59-72
12. Berton M., Benimetskaya L., Allemann E., Stein C.A., and Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur J Pharm Biopharm 47 (1999) 119-123
13. Zelphati O., and Szoka Jr. F.C. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 13 (1996) 1367-1372
14. Spankuch B., Steinhauser I., Wartlick H., Kurunci-Csacsko E., Strebhardt K.I., and Langer K. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 10 (2008) 223-234
15. Irache J.M., and Espuelas S. Albumin nanoparticles. In: Kumar C. (Ed). Biological and pharmaceutical nanomaterials (2006), Wiley-VCH, Weinheim
16. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., and Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257 (2003) 169-180
17. Weber C., Coester C., Kreuter J., and Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 194 (2000) 91-102
18. Lin W., Garnett M.C., Schacht E., Davis S.S., and Illum L. Preparation and in vitro characterization of HSA-mPEG nanoparticles. Int J Pharm 189 (1999) 161-170
19. Magee G.A., Halbert G.W., and Wilmott N. Effect of process variables on the in vitro degradation of protein microspheres. J Controlled Release 37 (1995) 11-19
20. Chen C.Q., Lin W., Coombes A.G., Davis S.S., and Illum L. Preparation of human serum albumin microspheres by a novel acetone-heat denaturation method. J Microencapsul 11 (1994) 395-407
21. Langer K. Peptide nanoparticles. In: Kumar C. (Ed). Biological and pharmaceutical nanomaterials (2006), Wiley-VCH, Weinheim 145-184
22. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54 (2002) 631-651
23. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32 (2004) e149
24. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., and Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12 (2004) 461-471
25. Steinhauser I., Spankuch B., Strebhardt K., and Langer K. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27 (2006) 4975-4983
26. Nobs L., Buchegger F., Gurny R., and Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 17 (2006) 139-145
27. Bibby D.C., Talmadge J.E., Dalal M.K., Kurz S.G., Chytil K.M., Barry S.E., et al. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 293 (2005) 281-290
28. Spankuch B., Heim S., Kurunci-Csacsko E., Lindenau C., Yuan J., Kaufmann M., et al. Down-regulation of polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 66 (2006) 5836-5846
29. Wartlick H., Spankuch-Schmitt B., Strebhardt K., Kreuter J., and Langer K. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Controlled Release 96 (2004) 483-495
30. Torrado J.J., Illum L., and Davis S. Particle size and size distribution of albumin microspheres produced by heat and chemical stabilization. Int J Pharm 51 (1989) 85-93
31. Zeng X.M., Martin G.P., and Marriot C. Albumin microspheres as a means of drug delivery to the lung: analysis of the effect of process variables on particle sizes using factorial design methodology. Int J Pharm 107 (1994) 205-210
32. Gupta P.K., and Perrier D.G. Albumin microspheres. I. Release characteristics of adriamycin. Int J Pharm 33 (1986) 137-146
33. Gupta P.K., Lam F.C., and Hung C.T. Albumin microspheres. IV. Effect of protein concentration and stabilization time on the release rate of adriamycin. Int J Pharm 51 (1989) 253-258
34. Vyas S.P., Bhatnager S., Gogoi P.J., and Jain N.K. Preparation and characterization of HSA-propranolol microspheres for nasal administration. Int J Pharm 69 (1991) 5-12
35. Arshady R. Albumin microspheres and microcapsules: methodology of manufacturing techniques. J Controlled Release 14 (1990) 111-131
36. Gupta P.K., Hung C.T., Lam F.C., and Perrier D.G. Albumin microspheres. III. Synthesis and characterization of microspheres containing adriamycin and magnetite. Int J Pharm 43 (1988) 167-177
37. Toub N., Malvy C., Fattal E., and Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 60 (2006) 607-620
38. Zon G. Oligonucleotide analogues as potential chemotherapeutic agents. Pharm Res 5 (1988) 539-549
39. Artemov D., Mori N., Okollie B., and Bhujwalla Z.M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49 (2003) 403-408
40. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
41. Waterman H., and Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490 (2001) 142-152